{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:50:27Z","timestamp":1790470227350,"version":"4.1.0"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.critrevonc.2016.04.020","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T13:47:05Z","timestamp":1462974425000},"page":"62-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Harnessing the immune system in acute myeloid leukaemia"],"prefix":"10.1016","volume":"103","author":[{"given":"Rebecca","family":"Austin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/ehm.10.80","article-title":"Vaccines as consolidation therapy for myeloid leukemia","volume":"4","author":"Alatrash","year":"2011","journal-title":"Expert Rev. Hematol."},{"issue":"7463","key":"10.1016\/j.critrevonc.2016.04.020_bib0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2010.324","article-title":"Interferon-[alpha] in acute myeloid leukemia: an old drug revisited","volume":"25","author":"Anguille","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.04.020_bib0020","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/leu.2012.145","article-title":"Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia","volume":"26","author":"Anguille","year":"2012","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.critrevonc.2016.04.020_bib0025","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0030","doi-asserted-by":"crossref","first-page":"OF13","DOI":"10.1158\/2159-8290.CD-RW2015-049","article-title":"PD-L1 upregulation drives escape from anti-CTLA4 and radiation therapy","volume":"5","year":"2015","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"22","key":"10.1016\/j.critrevonc.2016.04.020_bib0040","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2016.04.020_bib0045","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1073\/pnas.94.13.6886","article-title":"Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity","volume":"94","author":"Armstrong","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"24","key":"10.1016\/j.critrevonc.2016.04.020_bib0050","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1182\/blood-2011-11-391722","article-title":"Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase\/gp91(phox) expression and the PARP-1\/PAR pathway of apoptosis","volume":"119","author":"Aurelius","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc3907","article-title":"Haematological malignancies: at the forefront of immunotherapeutic innovation","volume":"15","author":"Bachireddy","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2016.04.020_bib0060","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood.V97.11.3574","article-title":"High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)","volume":"97","author":"Baer","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0065","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/0008-5472.CAN-08-2650","article-title":"Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans","volume":"69","author":"Baessler","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0070","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2009-06-227934","article-title":"CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells","volume":"115","author":"Baessler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0075","article-title":"Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia","author":"Baragano Raneros","year":"2014","journal-title":"Genes Immun."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri1859","article-title":"The SIRP family of receptors and immune regulation","volume":"6","author":"Barclay","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.leu.2404032","article-title":"Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia","volume":"20","author":"Behl","year":"2006","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.04.020_bib0090","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011: a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0095","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/leu.2014.233","article-title":"Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy","volume":"29","author":"Berlin","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2141.2009.08029.x","article-title":"Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis","volume":"149","author":"Berneman","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-12-2179","article-title":"Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance","volume":"73","author":"Berrien-Elliott","year":"2013","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0110","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","article-title":"In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors","volume":"59","author":"Berthon","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0115","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc1365","article-title":"Molecules and mechanisms of the graft-versus-leukaemia effect","volume":"4","author":"Bleakley","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0120","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2016.04.020_bib0125","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1182\/blood.V122.21.2696.2696","article-title":"Repeated dosing of anti-KIR (IPH2101) as maintenance therapy in ederly patients with acute myeloid leukemia","volume":"122","author":"Bourhis","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/bcj.2011.12","article-title":"FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes","volume":"1","author":"Brackertz","year":"2011","journal-title":"Blood Cancer J."},{"issue":"18","key":"10.1016\/j.critrevonc.2016.04.020_bib0135","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0198-8859(01)00381-0","article-title":"Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon","volume":"63","author":"Brouwer","year":"2002","journal-title":"Hum. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0145","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1101\/gr.165985.113","article-title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","volume":"24","author":"Brown","year":"2014","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2005-10-4073","article-title":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","volume":"108","author":"Brune","year":"2006","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2016.04.020_bib0155","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMoa031046","article-title":"Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia","volume":"350","author":"Bullinger","year":"2004","journal-title":"New Engl. J. Med."},{"issue":"26","key":"10.1016\/j.critrevonc.2016.04.020_bib0160","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1182\/blood-2011-02-337725","article-title":"Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia","volume":"117","author":"Buyse","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib0165","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1073\/pnas.1424869112","article-title":"APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation","volume":"112","author":"Cescon","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0170","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.0105-2896.2010.00893.x","article-title":"Effect of NKG2D ligand expression on host immune responses","volume":"235","author":"Champsaur","year":"2010","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0175","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3324\/haematol.13112","article-title":"High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome","volume":"93","author":"Chamuleau","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0180","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.leukres.2010.12.032","article-title":"High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2","volume":"35","author":"Chamuleau","year":"2011","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0185","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ni.2850","article-title":"The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions","volume":"15","author":"Chan","year":"2014","journal-title":"Nat. Immunol."},{"issue":"174","key":"10.1016\/j.critrevonc.2016.04.020_bib0190","doi-asserted-by":"crossref","first-page":"174ra27","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0195","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrd4506","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens","volume":"14","author":"Childs","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0205","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V93.3.780","article-title":"Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses","volume":"93","author":"Choudhury","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0210","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1182\/blood.V94.6.2048","article-title":"CD34+ acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells","volume":"94","author":"Cignetti","year":"1999","journal-title":"Blood"},{"issue":"203","key":"10.1016\/j.critrevonc.2016.04.020_bib0215","doi-asserted-by":"crossref","first-page":"203ra125","DOI":"10.1126\/scitranslmed.3006061","article-title":"MHC class I\u2013associated phosphopeptides are the targets of memory-like immunity in leukemia","volume":"5","author":"Cobbold","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0220","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0225","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1073\/pnas.0813192106","article-title":"Cytokine-induced memory-like natural killer cells","volume":"106","author":"Cooper","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0230","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.leukres.2008.06.014","article-title":"Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma","volume":"33","author":"Corm","year":"2009","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0235","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO;2-5","article-title":"Regulation of CD80\/B7-1 and CD86\/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition","volume":"28","author":"Costello","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0240","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1182\/blood.V99.10.3661","article-title":"Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia","volume":"99","author":"Costello","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0245","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.leu.2404485","article-title":"Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase","volume":"21","author":"Curti","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.critrevonc.2016.04.020_bib0250","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1182\/blood-2008-07-144485","article-title":"The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology","volume":"113","author":"Curti","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0255","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"224","key":"10.1016\/j.critrevonc.2016.04.020_bib0260","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0265","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.1990.tb00446.x","article-title":"Immunological definition of acute promyelocytic leukemia (FAB M3): a study of 39 cases","volume":"45","author":"De Rossi","year":"1990","journal-title":"Eur. J. Haematol."},{"issue":"13","key":"10.1016\/j.critrevonc.2016.04.020_bib0270","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1182\/blood-2006-03-006700","article-title":"The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function","volume":"108","author":"Della Chiesa","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0275","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations","volume":"106","author":"Dohner","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0280","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0285","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.12774","article-title":"Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis","volume":"165","author":"Dulphy","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0290","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0295","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.4049\/jimmunol.176.7.4113","article-title":"Immature NK cells suppress dendritic cell functions during the development of leukemia in a mouse model","volume":"176","author":"Ebata","year":"2006","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0300","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0305","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12032-010-9459-6","article-title":"Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells","volume":"28","author":"El Kholy","year":"2011","journal-title":"Med. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2016.04.020_bib0310","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2013-09-526590","article-title":"Immune evasion by oncogenic proteins of acute myeloid leukemia","volume":"123","author":"Elias","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2016.04.020_bib0315","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.4049\/jimmunol.176.11.6752","article-title":"The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells","volume":"176","author":"Fallarino","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0320","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","article-title":"Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction","volume":"109","author":"Fauriat","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0325","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.leu.2404720","article-title":"CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease","volume":"21","author":"Fevery","year":"2007","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.04.020_bib0330","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.18632\/oncotarget.1504","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia","volume":"5","author":"Folgiero","year":"2014","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.critrevonc.2016.04.020_bib0335","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development: maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0340","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/sj.leu.2404401","article-title":"Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells","volume":"20","author":"Gal","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0345","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.leukres.2015.04.007","article-title":"CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis","volume":"39","author":"Galli","year":"2015","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0350","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood.V81.5.1369.1369","article-title":"Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml\/RAR alpha present in acute promyelocytic leukemia cells","volume":"81","author":"Gambacorti-Passerini","year":"1993","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0355","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12013-014-9900-0","article-title":"Hypothesis: Tim-3\/Galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages","volume":"70","author":"Gao","year":"2014","journal-title":"Cell Biochem. Biophys."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib0360","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","article-title":"Human Vgamma9Vdelta2T cells specifically recognize and kill acute myeloid leukemic blasts","volume":"188","author":"Gertner-Dardenne","year":"2012","journal-title":"J. Immunol."},{"issue":"15","key":"10.1016\/j.critrevonc.2016.04.020_bib0365","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2016.04.020_bib0370","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Gleason","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib0375","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/01.TP.0000152118.51622.F9","article-title":"Augmented induction of CD4+CD25+ treg using monoclonal antibodies to CD200R","volume":"79","author":"Gorczynski","year":"2005","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0380","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/leu.2014.14","article-title":"Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues","volume":"28","author":"Goswami","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0385","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood-2006-07-032839","article-title":"A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells","volume":"109","author":"Graf","year":"2007","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2016.04.020_bib0390","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification: increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2016.04.020_bib0395","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1158\/1078-0432.CCR-08-1102","article-title":"Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells","volume":"14","author":"Greiner","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0400","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0405","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0092-8674(93)80044-F","article-title":"The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells","volume":"74","author":"Grignani","year":"1993","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0410","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0415","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1593\/neo.05703","article-title":"Soluble HLA-G molecules are increased during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages","volume":"8","author":"Gros","year":"2006","journal-title":"Neoplasia"},{"issue":"15","key":"10.1016\/j.critrevonc.2016.04.020_bib0420","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2012-03-419622","article-title":"A novel hierarchical prognostic model of AML solely based on molecular mutations","volume":"120","author":"Grossmann","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2016.04.020_bib0425","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"16","key":"10.1016\/j.critrevonc.2016.04.020_bib0430","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0435","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12307-012-0127-6","article-title":"Effector CD4 and CD8 T cells and their role in the tumor microenvironment","volume":"6","author":"Hadrup","year":"2013","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0440","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbmt.2008.08.001","article-title":"Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses","volume":"14","author":"Hallett","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0445","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (Anti\u2013PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0450","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.04.020_bib0455","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00262-011-1040-4","article-title":"Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity","volume":"60","author":"Hausler","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0460","first-page":"1022","article-title":"Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors","volume":"7","author":"Heiblig","year":"2015","journal-title":"World J. Stem Cells"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib0465","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0470","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1600-0609.2006.00679.x","article-title":"Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma","volume":"77","author":"Hentschel","year":"2006","journal-title":"Eur. J. Haematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.04.020_bib0475","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"5497","key":"10.1016\/j.critrevonc.2016.04.020_bib0480","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1126\/science.290.5497.1768","article-title":"Down-regulation of the macrophage lineage through interaction with OX2 (CD200)","volume":"290","author":"Hoek","year":"2000","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.critrevonc.2016.04.020_bib0485","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0490","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00241263","article-title":"Cellular expression and tissue distribution of the human LAG-3-encoded protein: an MHC class II ligand","volume":"39","author":"Huard","year":"1994","journal-title":"Immunogenetics"},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0495","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3: a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0500","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0002-9440(10)65321-7","article-title":"Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression","volume":"154","author":"Kageshita","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"95","key":"10.1016\/j.critrevonc.2016.04.020_bib0505","doi-asserted-by":"crossref","first-page":"3002842","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0510","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10637-015-0289-4","article-title":"Blinatumomab for the treatment of acute lymphoblastic leukemia","volume":"33","author":"Kaplan","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"26","key":"10.1016\/j.critrevonc.2016.04.020_bib0515","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","article-title":"A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS","volume":"113","author":"Keilholz","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0520","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.molonc.2014.07.011","article-title":"Acquired and intrinsic resistance in cancer immunotherapy","volume":"8","author":"Kelderman","year":"2014","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0525","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1749-6632.2012.06550.x","article-title":"TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia","volume":"1266","author":"Kikushige","year":"2012","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0530","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2016.04.020_bib0535","doi-asserted-by":"crossref","first-page":"e26491","DOI":"10.4161\/onci.26491","article-title":"Role of non-classical MHC class I molecules in cancer immunosuppression","volume":"2","author":"Kochan","year":"2013","journal-title":"Oncoimmunology"},{"issue":"20","key":"10.1016\/j.critrevonc.2016.04.020_bib0540","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0545","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0550","doi-asserted-by":"crossref","first-page":"pe330","DOI":"10.1038\/bcj.2015.58","article-title":"PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation","volume":"5","author":"Kong","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0555","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopha.2010.06.013","article-title":"Novel aspects of in vitro IL-2 or IFN-alpha enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction","volume":"64","author":"Konjevic","year":"2010","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib0560","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.4049\/jimmunol.178.9.5595","article-title":"CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy","volume":"178","author":"Kretz-Rommel","year":"2007","journal-title":"J. Immunol."},{"issue":"7104","key":"10.1016\/j.critrevonc.2016.04.020_bib0565","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","article-title":"Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9","volume":"442","author":"Krivtsov","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0570","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kronig","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0575","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0580","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","author":"Krupka","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0585","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00262-010-0929-7","article-title":"Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909","volume":"60","author":"Kuball","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0590","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"Genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","author":"Kumar","year":"2011","journal-title":"Genes Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0595","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood.V99.6.2146","article-title":"Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia","volume":"99","author":"LaBelle","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0600","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2009.12.001","article-title":"Leukemia stem cells","volume":"20","author":"Lane","year":"2010","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0605","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2141.2006.06472.x","article-title":"CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis","volume":"136","author":"Laurent","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.critrevonc.2016.04.020_bib0610","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0615","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0145-2126(01)00082-0","article-title":"Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia","volume":"25","author":"Lee","year":"2001","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0620","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1365-2567.2002.01526.x","article-title":"Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division","volume":"107","author":"Lee","year":"2002","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0625","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jdermsci.2005.06.008","article-title":"IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells","volume":"40","author":"Lee","year":"2005","journal-title":"J. Dermatol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0630","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.canlet.2014.08.027","article-title":"Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia","volume":"354","author":"Lee","year":"2014","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.critrevonc.2016.04.020_bib0635","first-page":"6880","article-title":"Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification","volume":"7","author":"Li","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib0640","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib0645","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2012.87","article-title":"Natural killer cell immune escape in acute myeloid leukemia","volume":"26","author":"Lion","year":"2012","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.critrevonc.2016.04.020_bib0650","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib0655","doi-asserted-by":"crossref","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0660","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0665","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.bmt.1700756","article-title":"The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia","volume":"19","author":"Lowdell","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0670","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2141.2002.03495.x","article-title":"Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells","volume":"117","author":"Lowdell","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2016.04.020_bib0675","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1517\/14728222.11.10.1299","article-title":"TRAIL in cancer therapy: present and future challenges","volume":"11","author":"M\u00e9rino","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib0680","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1073\/pnas.0900089106","article-title":"Dysregulated gene expression networks in human acute myelogenous leukemia stem cells","volume":"106","author":"Majeti","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0685","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0690","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1038\/sj.leu.2402742","article-title":"Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes","volume":"16","author":"Makita","year":"2002","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.critrevonc.2016.04.020_bib0695","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0700","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2014-02-514745","article-title":"The biology of graft-versus-host disease: experimental systems instructing clinical practice","volume":"124","author":"Markey","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0705","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/ehm.10.30","article-title":"Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia","volume":"3","author":"Martner","year":"2010","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0710","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1349-7006.2006.00356.x","article-title":"Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts","volume":"98","author":"Masuda","year":"2007","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0715","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4049\/jimmunol.156.3.1126","article-title":"B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct","volume":"156","author":"Matulonis","year":"1996","journal-title":"J. Immunol."},{"issue":"33","key":"10.1016\/j.critrevonc.2016.04.020_bib0720","doi-asserted-by":"crossref","first-page":"13576","DOI":"10.1073\/pnas.1301891110","article-title":"Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation","volume":"110","author":"Miraki-Moud","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0725","series-title":"Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer","author":"Mitelman","year":"2015"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0730","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0735","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.2000.02345.x","article-title":"Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia","volume":"111","author":"Mizuno","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0740","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-0609.2004.00248.x","article-title":"Hematologic and molecular spontaneous remission following sepsis in acute monoblastic leukemia with translocation (9;11): a case report and review of the literature","volume":"73","author":"Muller","year":"2004","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0745","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0750","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.374","article-title":"In vivo eradication of MLL\/ENL leukemia cells by NK cells in the absence of adaptive immunity","volume":"28","author":"Nakata","year":"2014","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.critrevonc.2016.04.020_bib0755","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1182\/blood-2013-11-536219","article-title":"c-Myc regulates expression of NKG2D ligands ULBP1\/2\/3 in AML and modulates their susceptibility to NK-mediated lysis","volume":"123","author":"Nanbakhsh","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2016.04.020_bib0760","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1158\/0008-5472.CAN-15-1082","article-title":"A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1","volume":"75","author":"Ngiow","year":"2015","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0765","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1476-5381.2011.01753.x","article-title":"Pharmacological modulation of GITRL\/GITR system: therapeutic perspectives","volume":"165","author":"Nocentini","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0770","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4049\/jimmunol.178.1.85","article-title":"Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation","volume":"178","author":"North","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0775","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2004-07-2585","article-title":"Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias","volume":"105","author":"Nowbakht","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0780","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CJI.0b013e3181f3cc5c","article-title":"Wilms Tumor Protein 1 (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow","volume":"34","author":"Ochsenreither","year":"2011","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0785","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00262-011-1099-y","article-title":"Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients","volume":"61","author":"Ochsenreither","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0790","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0795","first-page":"485","article-title":"Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy","volume":"18","author":"Osman","year":"1999","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0800","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/86515","article-title":"AML1-ETO downregulates the granulocytic differentiation factor C\/EBPalpha in t(8;21) myeloid leukemia","volume":"7","author":"Pabst","year":"2001","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0805","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2016.04.020_bib0810","doi-asserted-by":"crossref","first-page":"11842","DOI":"10.1073\/pnas.2034201100","article-title":"Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?","volume":"100","author":"Passegu\u00e9","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0815","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/imt.15.6","article-title":"CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?","volume":"7","author":"Pegram","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0820","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2004-09-3548","article-title":"Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)","volume":"105","author":"Pende","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0825","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.molimm.2004.07.028","article-title":"PVR (CD155) and nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis","volume":"42","author":"Pende","year":"2005","journal-title":"Mol. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0830","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/cdd.2015.3","article-title":"The role of CD95 and CD95 ligand in cancer","volume":"22","author":"Peter","year":"2015","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.04.020_bib0835","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0840","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/bjc.1988.221","article-title":"Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission","volume":"58","author":"Pizzolo","year":"1988","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib0845","first-page":"331","article-title":"Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients","volume":"50","author":"Polakova","year":"2003","journal-title":"Neoplasma"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0850","first-page":"279","article-title":"Role of natural killer cells in cancer","volume":"12","author":"Pross","year":"1993","journal-title":"Nat. Immun."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib0855","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","article-title":"Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia","volume":"124","author":"Rajasagi","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2016.04.020_bib0860","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.4049\/jimmunol.176.11.6434","article-title":"Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance\/ignorance to melanoma differentiation antigens and enhances antitumor immunity","volume":"176","author":"Ramirez-Montagut","year":"2006","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.04.020_bib0865","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nri2604","article-title":"Oncogenic stress sensed by the immune system: role of natural killer cell receptors","volume":"9","author":"Raulet","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0870","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0301-472X(01)00768-8","article-title":"Expression of CD86 in acute myelogenous leukemia is a marker of dendritic\/monocytic lineage","volume":"30","author":"Re","year":"2002","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0875","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0880","first-page":"612","article-title":"TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL","volume":"90","author":"Riccioni","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0885","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/cdd.2014.89","article-title":"Regulation of hematopoietic and leukemic stem cells by the immune system","volume":"22","author":"Riether","year":"2015","journal-title":"Cell Death Differ."},{"issue":"11","key":"10.1016\/j.critrevonc.2016.04.020_bib0890","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib0895","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1182\/blood-2010-12-325746","article-title":"Type I-IFNs control GVHD and GVL responses after transplantation","volume":"118","author":"Robb","year":"2011","journal-title":"Blood"},{"issue":"9948","key":"10.1016\/j.critrevonc.2016.04.020_bib0900","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0905","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"13","key":"10.1016\/j.critrevonc.2016.04.020_bib0910","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2009-02-206532","article-title":"Preclinical characterization of 1-7F9: a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells","volume":"114","author":"Romagne","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0915","first-page":"205796","article-title":"Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer","volume":"2014","author":"Romee","year":"2014","journal-title":"Scientifica (Cairo)"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2016.04.020_bib0920","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0925","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bcmd.2007.06.029","article-title":"NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation","volume":"40","author":"Ruggeri","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"issue":"18","key":"10.1016\/j.critrevonc.2016.04.020_bib0930","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1158\/1078-0432.CCR-13-0551","article-title":"Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class","volume":"19","author":"Rutledge","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.critrevonc.2016.04.020_bib0935","doi-asserted-by":"crossref","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0940","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.4049\/jimmunol.167.7.4059","article-title":"Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies","volume":"167","author":"Salih","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0945","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood-2003-01-0019","article-title":"Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia","volume":"102","author":"Salih","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0950","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.exphem.2006.03.006","article-title":"The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans","volume":"34","author":"Salih","year":"2006","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.04.020_bib0955","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00262-011-1050-2","article-title":"Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands","volume":"60","author":"Sanchez-Correa","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib0960","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/icb.2011.15","article-title":"Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients","volume":"90","author":"Sanchez-Correa","year":"2012","journal-title":"Immunol. Cell Biol."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0965","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood-2004-01-0064","article-title":"In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis","volume":"104","author":"Saudemont","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib0970","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2002-01-0163","article-title":"CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia","volume":"100","author":"Scheibenbogen","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib0975","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-01-071001","article-title":"The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens","volume":"110","author":"Scheich","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2016.04.020_bib0980","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib0985","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/10428190500301306","article-title":"Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches","volume":"47","author":"Scholl","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib0990","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1053\/j.seminoncol.2008.04.004","article-title":"Deregulation of signaling pathways in acute myeloid leukemia","volume":"35","author":"Scholl","year":"2008","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib0995","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.04.020_bib1000","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1517\/14712598.2015.1051028","article-title":"Programmed death-1 checkpoint blockade in acute myeloid leukemia","volume":"15","author":"Sehgal","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib1005","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ijc.25791","article-title":"Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia","volume":"129","author":"Shenghui","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib1010","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib1015","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.04.020_bib1020","doi-asserted-by":"crossref","first-page":"e23619","DOI":"10.4161\/onci.23619","article-title":"Interferon alpha may be back on track to treat acute myeloid leukemia","volume":"2","author":"Smits","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","article-title":"Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity","volume":"90","author":"Smyth","year":"2006","journal-title":"Adv. Immunol."},{"issue":"23","key":"10.1016\/j.critrevonc.2016.04.020_bib1030","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"New Engl. J. Med."},{"issue":"15","key":"10.1016\/j.critrevonc.2016.04.020_bib1035","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib1040","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib1045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jjco\/hyp194","article-title":"WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy","volume":"40","author":"Sugiyama","year":"2010","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib1050","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib1055","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.4049\/jimmunol.178.12.7540","article-title":"Type I IFN contributes to NK cell homeostasis, activation, and antitumor function","volume":"178","author":"Swann","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1060","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1065","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","article-title":"Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia","volume":"15","author":"Szczepanski","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00262-009-0724-5","article-title":"Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors","volume":"59","author":"Szczepanski","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1075","first-page":"478","article-title":"Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia","volume":"10","author":"Tajima","year":"1996","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.critrevonc.2016.04.020_bib1080","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-04-2672","article-title":"Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia","volume":"11","author":"Tamura","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib1085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/2040620715588916","article-title":"CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)","volume":"6","author":"Tasian","year":"2015","journal-title":"Ther. Adv. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib1090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2051-1426-1-13","article-title":"Immune evasion in acute myeloid leukemia: current concepts and future directions","volume":"1","author":"Teague","year":"2013","journal-title":"J. ImmunoTher. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib1095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc989","article-title":"Disruption of differentiation in human cancer: AML shows the way","volume":"3","author":"Tenen","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2016.04.020_bib1100","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"The Cancer Genome Atlas Research Network,","year":"2013","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib1105","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.leu.2404559","article-title":"CD200 as a prognostic factor in acute myeloid leukaemia","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.critrevonc.2016.04.020_bib1110","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/sj.leu.2404961","article-title":"Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.critrevonc.2016.04.020_bib1115","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib1120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2249.1990.tb05241.x","article-title":"Loss of natural killer activity as an indicator of relapse in acute leukaemia","volume":"80","author":"Tratkiewicz","year":"1990","journal-title":"Clin. Exp. Immunol."},{"issue":"27","key":"10.1016\/j.critrevonc.2016.04.020_bib1125","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib1130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0145-2126(99)00037-5","article-title":"Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)","volume":"23","author":"Tsuboi","year":"1999","journal-title":"Leuk. Res."},{"issue":"7547","key":"10.1016\/j.critrevonc.2016.04.020_bib1135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib1140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.12637","article-title":"Wilms' tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses","volume":"164","author":"Uttenthal","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"16","key":"10.1016\/j.critrevonc.2016.04.020_bib1145","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa040465","article-title":"Prognostically useful gene-expression profiles in acute myeloid leukemia","volume":"350","author":"Valk","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib1150","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1634\/theoncologist.2011-0240","article-title":"Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials","volume":"17","author":"Van Driessche","year":"2012","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.04.020_bib1155","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.04.020_bib1160","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.leu.2404279","article-title":"Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions","volume":"20","author":"Verheyden","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/sj.leu.2405040","article-title":"NK cell receptors and their ligands in leukemia","volume":"22","author":"Verheyden","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1170","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/sj.leu.2403525","article-title":"Identification of natural killer cell receptor phenotypes associated with leukemia","volume":"18","author":"Verheyden","year":"2004","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.critrevonc.2016.04.020_bib1175","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","article-title":"A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission","volume":"120","author":"Vey","year":"2012","journal-title":"Blood"},{"issue":"6127","key":"10.1016\/j.critrevonc.2016.04.020_bib1180","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib1185","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1046\/j.1365-2141.2003.04212.x","article-title":"Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia","volume":"120","author":"Vollmer","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"June (3)","key":"10.1016\/j.critrevonc.2016.04.020_bib1190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1586\/17474086.2014.896190","article-title":"Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia","volume":"7","author":"Walter","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1195","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1600-0609.2005.00537.x","article-title":"Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients","volume":"75","author":"Wang","year":"2005","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib1200","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1600-0609.2005.00537.x","article-title":"Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients","volume":"75","author":"Wang","year":"2005","journal-title":"Eur. J. Haematol."},{"issue":"2\u20133","key":"10.1016\/j.critrevonc.2016.04.020_bib1205","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0014-5793(00)01112-1","article-title":"Identification of a melanoma antigen, PRAME, as a BCR\/ABL-inducible gene","volume":"466","author":"Watari","year":"2000","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib1210","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.leu.2401982","article-title":"HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse","volume":"15","author":"Wetzler","year":"2001","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib1215","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.04.020_bib1220","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.04.020_bib1225","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1078-0432.CCR-08-1305","article-title":"Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation","volume":"15","author":"Wu","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib1230","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1582-4934.2008.00175.x","article-title":"Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia","volume":"12","author":"Yan","year":"2008","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib1235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11206410-000000000-00000","article-title":"Histamine dihydrochloride: in the management of acute myeloid leukaemia","volume":"71","author":"Yang","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1240","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-0263","article-title":"Boosting cancer immunotherapy with anti-CD137 antibody therapy","author":"Yonezawa","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib1245","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J. Immunol."},{"issue":"21","key":"10.1016\/j.critrevonc.2016.04.020_bib1250","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1182\/blood.V122.21.4196.4196","article-title":"TIM-3, a leukemia stem cell marker, plays a role In leukemic transformation through autocrine stimulatory signaling by its ligand, galectin-9","volume":"122","author":"Yuda","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.04.020_bib1255","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.intimp.2005.02.003","article-title":"Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells","volume":"5","author":"Zhang","year":"2005","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.04.020_bib1260","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2016.04.020_bib1265","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.04.020_bib1270","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1189\/jlb.0113006","article-title":"Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia","volume":"94","author":"Zhou","year":"2013","journal-title":"J. Leukoc. Biol."},{"issue":"10","key":"10.1016\/j.critrevonc.2016.04.020_bib1275","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2010-03-270991","article-title":"High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia","volume":"116","author":"de Jonge","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.020_bib1280","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/imt.09.84","article-title":"Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia","volume":"2","author":"van Luijn","year":"2010","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.04.020_bib1285","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1158\/0008-5472.CAN-10-3689","article-title":"Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells","volume":"71","author":"van Luijn","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.04.020_bib1290","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.leukres.2014.03.014","article-title":"High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia","volume":"38","author":"van den Ancker","year":"2014","journal-title":"Leuk. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T01:21:10Z","timestamp":1692321670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":258,"alternative-id":["S1040842816301068"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.04.020","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing the immune system in acute myeloid leukaemia","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}